<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Auxilium Pharmaceuticals Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/auxilium-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACOR) Company News for August 2, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405</link>
		<comments>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405#comments</comments>
		<pubDate>Tue, 02 Aug 2011 21:23:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[KEG]]></category>
		<category><![CDATA[Key Energy Services Inc]]></category>
		<category><![CDATA[Old National BanCorporation]]></category>
		<category><![CDATA[ONB]]></category>
		<category><![CDATA[PAET]]></category>
		<category><![CDATA[PAETEC Holding Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80405</guid>
		<description><![CDATA[•    Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion•    Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts&#8217; estimate for a loss of $0.19 per share. Revenues for the quarter increased 30.5% year-over-year to $65.9 million •    Humana (NYSE:HUM) reported Q2 EPS of $2.50, beating the Zacks Consensus Estimate of $2.07 per share. Revenues increased 8.1% year-over-year to $9.28 billion, lower than the Zacks Consensus Estimate of $9.32 billion •    Acorda Therapeutics (NASDAQ:ACOR) posted Q2 EPS of $0.01. Revenues for the pharma company rose 52.6% year-over-year to $65.3 million •    Share prices of Old National ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories Earns FDA Approval of AndroGel</title>
		<link>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465</link>
		<comments>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465#comments</comments>
		<pubDate>Fri, 06 May 2011 01:36:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73465</guid>
		<description><![CDATA[Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product in its portfolio for this indication – AndroGel 1%. However, Abbott Labs said that AndroGel 1.62% has the ability to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%. Results from a study showed that 82% of patients taking AndroGel 1.62% achieved a normal average testosterone level on day 112. AndroGel 1.62% will be available from the second quarter of 2011. AndroGel 1.62% became a part of Abbott Labs’ portfolio with its Feb 2010 acquisition of Solvay Pharmaceuticals. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly&#8217;s Axiron Testosterone Deficiency Drug Launched in the U.S.</title>
		<link>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638</link>
		<comments>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638#comments</comments>
		<pubDate>Tue, 05 Apr 2011 15:52:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70638</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Axiron Rights Acquired in March 2010 Eli Lilly acquired exclusive worldwide rights from Australian company, Acrux, to commercialize Axiron in March 2010. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. The FDA approval of Axiron triggered a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Men’s Health Portfolio ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company Gets FDA Approval of Axiron</title>
		<link>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396</link>
		<comments>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60396</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Eli Lilly acquired exclusive worldwide rights to commercialize Axiron earlier this year. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. With Axiron having gained FDA approval, Acrux now stands to receive a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. The addition of Axiron has helped boost Eli Lilly’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss</title>
		<link>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650</link>
		<comments>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:56:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58650</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues helped the company post a lower loss. Net revenues increased 27.3% to $53.6 million in the quarter, short of the Zacks Consensus Estimate of $55 million. Quarter in Detail During the reported quarter, Testim sales in the US grew 17.9% to $47.4 million, mainly due to price increases and higher demand. Prescriptions increased 7.9% from the year-ago period. However, Testim faces significant competition in the form of Abbott’s (ABT) AndroGel. We note that Testim’s share of the US testosterone gel market declined in September. According to IMS Health, Testim exited the month of Sep 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/auxl-auxilium-pharmaceuticals-reports-narrower-loss/58650/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals Reports Quarterly Loss That Narrows</title>
		<link>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473</link>
		<comments>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473#comments</comments>
		<pubDate>Thu, 06 May 2010 23:22:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Health Net Inc.]]></category>
		<category><![CDATA[HNT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36473</guid>
		<description><![CDATA[Strong Testim sales helped Auxilium Pharmaceuticals, Inc. (AUXL) report a narrower-than-expected net loss of 18 cents per share in the first quarter of 2010, 13 cents below the Zacks Consensus Estimate and year-ago net loss of 31 cents. Net revenues increased 31.1% to $45.5 million in the first quarter. During the reported quarter, Testim sales in the US grew 35% to $43.9 million, with prescriptions growing 14.8% from the year-ago period. According to IMS Health, Testim exited the month of Mar 2010 with a 22.4% share of the US testosterone gel market, up from the 21.6% share in the year-ago period. Worldwide Testim revenues were $44.2 million including product shipments outside the US. Auxilium expects Testim revenues in the range of $185 million to $195 million in 2010. Net revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/auxl-auxilium-pharmaceuticals-reports-quarterly-loss-that-narrows/36473/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company Expands Men&#8217;s Health Range</title>
		<link>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935</link>
		<comments>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:27:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30935</guid>
		<description><![CDATA[Eli Lilly and Co. (LLY) recently entered into a deal with Australian company, Acrux, which should help strengthen Lilly’s men’s health portfolio. Lilly acquired exclusive worldwide rights to commercialize Axiron, which is currently being reviewed by the US Food and Drug Administration (FDA) for the treatment of testosterone deficiency (hypogonadism) in men. As per the terms of the deal, Lilly will make an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. Lilly will also pay $87 million to Acrux on the receipt of FDA approval for the product. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Lilly expects to incur a charge of 3 cents related to this transaction in the first quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals&#8217; Xiaflex Awarded FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912</link>
		<comments>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912#comments</comments>
		<pubDate>Wed, 03 Feb 2010 20:19:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26912</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) recently received a major boost when the U.S. Food and Drug Administration (FDA) granted approval to Xiaflex for the treatment of adult Dupuytren&#8217;s contracture patients with a palpable cord. The approval comes several months after an FDA advisory panel voted unanimously in favor of approving the product. Shares were up 9.5% in after-market trading. Dupuytren’s contracture is a condition that affects the connective tissue in the palm known as palmar fascia. The company estimates that approximately 240,000 Dupuytren’s candidates could exist in the U.S. and the EU. This represents significant commercial opportunity for Auxilium and the company could capture a significant share of the market as Xiaflex is the first and only FDA-approved non-surgical treatment for Dupuytren&#8217;s contracture. The FDA is requiring the company to make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/03/auxl-auxilium-pharmaceuticals-xiaflex-awarded-fda-approval/26912/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process</title>
		<link>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897</link>
		<comments>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25897</guid>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization Application (MAA) for Xiaflex has commenced in the European Union. Pfizer was informed by the European Medicines Agency (EMEA) that the Xiaflex MAA has completed the validation phase successfully resulting in the commencement of the review process on Jan 21, 2010. Auxilium is now eligible to receive a $15 million milestone payment from Pfizer based on the commencement of the review process. The development, commercialization and supply agreement with Pfizer for Xiaflex covers Europe and certain Eurasian countries. Going forward, Auxilium can earn an additional $135 million in regulatory milestones and $260 million in sales milestones, along with a tiered double-digit royalty on sales at Pfizer. Pfizer and Auxilium are currently seeking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/auxl-auxilium-pharmaceuticals-and-pfizer-announces-eu-review-process/25897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Hits FDA Roadblock With Aveed</title>
		<link>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623</link>
		<comments>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:32:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22623</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) hit a roadblock related to the approval of Aveed. Recently, the company received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its injectable testosterone product Aveed for men diagnosed with low testosterone, also known as hypogonadism. The FDA is concerned about the adverse events including post-injection anaphylactic reaction and pulmonary oil microembolism. In the CRL, the company has been asked to address these concerns. Additionally, the FDA has made it clear that it is not satisfied with the proposed Risk Evaluation and Mitigation Strategy (REMS) adopted by the company. Aveed, known as Nebido outside the US, has been approved in 86 countries worldwide and is available in more than 50 countries across Europe, Asia Pacific ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Auxilium Pharma Awaiting FDA Decision</title>
		<link>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578</link>
		<comments>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578#comments</comments>
		<pubDate>Wed, 14 Oct 2009 17:08:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17578</guid>
		<description><![CDATA[Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable recommendation from the FDA’s Arthritis Advisory Committee for Xiaflex for the treatment of Dupuytren’s Contracture. Dupuytren’s Contracture is a condition that affects the connective tissue in the palm known as palmar fascia. The company estimates that approximately 240,000 Dupuytren’s candidates could exist in the U.S. and the EU. This represents significant commercial opportunity for Auxilium. Xiaflex is also being studied for the treatment of Peyronie’s disease and frozen shoulder syndrome. According to the company, there are at least 450,000 potential patients annually in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/auxl-auxilium-pharma-awaiting-fda-decision/17578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Buys US Rights to Fortesta</title>
		<link>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788</link>
		<comments>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:43:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13788</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review. Fortesta is a 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. The product uses a metered dose delivery system for adjustment of dosage according to individual needs. Fortesta is already available in Europe. Under terms of the deal, Endo will make an upfront payment of $10 million to ProStrakan and another $40 million by the end of 2010 on achievement of regulatory and commercial milestones. Endo has also agreed to pay an additional $160 million on realization of certain sales targets. ProStrakan will supply Fortesta to Endo in the U.S. for an undisclosed supply ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AUXL) Trading FDA Decisions with Calendar Spreads</title>
		<link>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058</link>
		<comments>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058#comments</comments>
		<pubDate>Thu, 16 Jul 2009 23:06:51 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10058</guid>
		<description><![CDATA[Joe Kunkle, The Investment U Research Team FDA approvals/rejections of drugs can make or break a Biotech company. These decisions can be incredibly volatile and profitable if you’re positioned correctly. There have been instances where shares lose more than three-fourths of its value and other cases where a company rises 900% or more in a single day (like Vanda Pharmaceuticals recently). In most instances, it’s pretty clear when the FDA will make a decision on a key drug, often named the PDUFA data. Also, companies generally make available dates that it will present top line data from drugs, before it submits it to the FDA for approval of an NDA (New Drug Application). The information on FDA decisions and announcement dates are out there. And many talented investors make a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/16/auxl-trading-fda-decisions-with-calendar-spreads/10058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

